89bio (ETNB) Competitors

89bio (NASDAQ:ETNB) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

Does the media prefer ETNB or GRFS?

In the previous week, 89bio had 1 more articles in the media than Grifols. MarketBeat recorded 5 mentions for 89bio and 4 mentions for Grifols. 89bio's average media sentiment score of 1.11 beat Grifols' score of 1.04 indicating that 89bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
89bio	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Grifols	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has preferable valuation and earnings, ETNB or GRFS?

Grifols has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
89bio	N/A	N/A	-$142.19M	-$3.38	-3.04
Grifols	$7.21B	0.86	$64.20M	$1.17	7.71

Which has more volatility & risk, ETNB or GRFS?

89bio has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.

Is ETNB or GRFS more profitable?

Grifols' return on equity of 0.00% beat 89bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
89bio	N/A	-59.58%	-52.21%
Grifols	N/A	N/A	N/A

Do analysts prefer ETNB or GRFS?

89bio presently has a consensus price target of $26.43, suggesting a potential upside of 157.09%. Given 89bio's higher probable upside, analysts clearly believe 89bio is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
89bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Grifols	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Does the MarketBeat Community believe in ETNB or GRFS?

Grifols received 237 more outperform votes than 89bio when rated by MarketBeat users. However, 61.50% of users gave 89bio an outperform vote while only 56.23% of users gave Grifols an outperform vote.

Company	Underperform	Outperform
89bio	Outperform Votes 115 61.50%	Underperform Votes 72 38.50%
Grifols	Outperform Votes 352 56.23%	Underperform Votes 274 43.77%

Summary

Grifols beats 89bio on 8 of the 15 factors compared between the two stocks.